Attorneys:
Bloomberg BNA’s Medical Devices Law & Industry Report quotes life sciences partner Gregory Levine (Washington, D.C.) in a Dec. 10 article that examines the FDA’s increased monitoring of companies marketing direct-to-consumer drug metabolism genetic tests. Mr. Levine explains that the effect of the letters to genetic test makers is to inform them that they may be marketing an illegal product, but the FDA is not using a warning letter at this stage.
Stay Up To Date with Ropes & Gray
Subscribe to Our Podcast
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Follow Us on Social
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
Join Our Mailing List
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.